Because ALK inhibitors such as crizotinib, ceritinib, and alectinib are currently available and FDA approved for ALK-fusion positive NSCLC, patients with advanced ALK fusion-positive thyroid cancer may respond to ALK inhibitors. This evidence concerns the gene ALK and thyroid gland carcinoma.